what are the risks of tirzepatide Benefits Injections The RISKS & BENEFITS of

GLP-1 Drugs, Obesity & Surgical Infection Risk What the 2026 Evidence Means for IPC HOSPITAL INFECTION CONTROL TIP OF THE DAY 027 GLP-1 Drugs, Obesity & Surgical Infection Risk What the 2026 Evidence Means for IPC 1 WHY IT MATTERS 2026 is the year GLP-1 receptor agonists went mainstream globally oral semaglutide approved by FDA in December 2025, tirzepatide expanding indications, Indian patent expiries imminent, and one in eight adults now on a GLP-1 medication in some markets

And we're guessing you do too

This physiological response can slow the rate of weight loss or, if caloric intake is not adjusted accordingly, potentially lead to weight stabilisation or modest regain

When gastric emptying is delayed, lying down increases the chance of acid reflux and worsens nausea